A high dose of pociredir, Fulcrum Therapeutics’ investigational oral therapy for sickle cell disease (SCD), was associated with…
Andrea Lobo, PhD
Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo, PhD
Having a low household- or neighborhood-level socioeconomic status is not significantly associated with a higher risk of stroke in children…
Disc Medicine has launched a small clinical trial to test DISC-3405, its treatment candidate for reducing iron levels and…
New research shows that Black men with sickle cell disease (SCD) become biological parents at a lower rate than similarly…
Fentanyl may be a feasible, safe, and effective option when administered intranasally (into the nose), to manage acute moderate to…
The investigational gene-editing therapy OTQ923 resulted in normalization of the speed of blood flow in the brain of three adults…
Most people with sickle cell disease (SCD) seem to meet or exceed current physical activity recommendations for the general…
From illuminating public buildings in red to candlelight vigils and walks, supporters are gearing up to raise awareness and increase…
Meningitis — an inflammation of the protective membranes surrounding the brain and spinal cord — remains associated with a case-fatality…
Top-line data from the Phase 3 part of RISE UP, a clinical trial testing mitapivat in people with sickle…